Pfizer’s Abrocitinib Quick Off The Mark In Atopic Dermatitis
Top-Line Results From Third Phase III Study
Pfizer’s next-generation JAK1 inhibitor, abrocitinib, continues to show beneficial effects in atopic dermatitis (eczema), in the JADE COMPARE study, comparable to the positive control dupilumab and, in the case of itch, with a faster onset at the higher dose.
